SCHEMBL1832936

SCHEMBL1832936

CSc1nccc(Oc2ccc(Nc3nnc(-c4ccccc4)c4ccccc34)cc2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 3/20 0.54
AURKB Q96GD4 2/20 0.54
TPX2 Q9ULW0 2/20 0.54
MAPT P10636 5/20 0.49
LMNA P02545 1/20 0.49
ENPP3 O14638 3/20 0.46
GAA P10253 2/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
TP53 P04637 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
KDR P35968 1/20 0.45
NPSR1 Q6W5P4 2/20 0.45
POLB P06746 3/20 0.44
THRB P10828 2/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
HTT P42858 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL580931 0.83 AURKA (0.77) AURKAAURKBTPX2MAPTLMNA
Hydrochloric Acid SCHEMBL580311 0.82 AURKA (0.75) AURKAAURKBTPX2MAPTLMNA
SCHEMBL1832652 0.79 KDR (0.55) AURKAAURKBTPX2MAPTLMNA
SCHEMBL3021512 0.75 MAPT (0.81) MAPTLMNAENPP3GAACA9
SCHEMBL1832096 0.74 KDR (0.48) AURKAAURKBTPX2MAPTLMNA
SCHEMBL9988170 0.74 KDR (0.48) AURKAAURKBTPX2MAPTLMNA
SCHEMBL9121662 0.74 HTT (0.59) MAPTLMNAGAAMEN1KMT2A
SCHEMBL15663469 0.74 AURKA (0.51) AURKAAURKBTPX2MAPTLMNA
SCHEMBL17366294 0.73 AURKA (0.64) AURKAAURKBTPX2MAPTLMNA
SCHEMBL580535 0.73 AURKA (0.59) AURKAAURKBTPX2MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2321298-B1 AURORA KINASE MODULATORS AND METHODS OF USE AMGEN INC (US) 2013-10-02 EP claimed
US-20110301162-A1 AURORA KINASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-12-08 US claimed
EP-2321298-A2 AURORA KINASE MODULATORS AND METHODS OF USE Amgen Inc. (US) 2011-05-18 EP claimed
WO-2010017240-A2 AURORA KINASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2010-02-11 WO claimed
EP-2321298-B1 AURORA KINASE MODULATORS AND METHODS OF USE AMGEN INC (US) 2013-10-02 EP disclosed
US-20110301162-A1 AURORA KINASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-12-08 US disclosed
US-20110301162-A1 AURORA KINASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-12-08 US disclosed
US-20110301162-A1 AURORA KINASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-12-08 US disclosed
EP-2321298-A2 AURORA KINASE MODULATORS AND METHODS OF USE Amgen Inc. (US) 2011-05-18 EP disclosed
WO-2010017240-A2 AURORA KINASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2010-02-11 WO disclosed
WO-2010017240-A2 AURORA KINASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301162-A1 AURORA KINASE MODULATORS AND METHODS OF USE AURKC, AURKA, CDK1 AURKA 2/4885AURKB 4/4885TPX2 314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.